NCT07314723 2026-01-02
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06823427 2025-03-21
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Recruiting
NCT06592326 2024-09-19
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT05302284 2023-12-18
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT04773951 2021-08-24
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT04211012 2020-11-13
A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04568304 2020-09-29
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Unknown